All Releases
 |
Dynavax Prices Public Offering of Common Stock
May 9, 2012
|
9.8 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 05/09/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock, offered at a price to the public of $4.25 per share. The gross proceeds to Dynavax from this offering are expected to be approximately $74.4 million...
|
|
Dynavax Announces Proposed Public Offering of Common Stock
May 8, 2012
|
9.1 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 05/08/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of its...
|
|
Dynavax Embarks on Transition to Commercialization
May 8, 2012
|
10.9 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 05/08/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today, that following the recent submission of the U.S. Biologics License Application (BLA) to the Food and Drug Administration (FDA), it intends to begin developing a commercial operation capable of independently launching HEPLISAV™ in ...
|
|
Dynavax Reports First Quarter 2012 Financial Results
Apr 27, 2012
|
11.1 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 04/27/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2012, including $106.9 million in cash, cash equivalents and marketable securities at March 31, 2012. This compared to $114 million at December 31, 2011. Total cash for the first qua...
|
|
Dynavax Reports HEPLISAV(TM) BLA Submission
Apr 26, 2012
|
9.5 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 04/26/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it has submitted a U.S. Biologics License Application (BLA) to the Food and Drug Administration (FDA) for HEPLISAV, pursuing an indication for immunization against infection caused by all known subtypes of hepatitis B virus in adult...
|
|
Dynavax Reports Final Phase 3 Data for HEPLISAV(TM) in CKD Patients and New Data From Booster Trial in Hemodialysis Patients
Mar 27, 2012
|
12.2 KB |
|
| |
BERKELEY, CA -- (Marketwire) -- 03/27/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced final data from a pivotal Phase 3 trial in patients with chronic kidney disease (CKD) demonstrating early seroprotection and the durability of the immune response to HEPLISAV compared to Engerix-B®. In October 2011, Dynavax reported...
|
|
Phase 3 Data on HEPLISAV(TM) in Adults Aged 40-70 Published in VACCINE
Mar 13, 2012
|
10.0 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 03/13/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that results of an early Phase 3 trial (HBV-04) of HEPLISAV™ investigational hepatitis B vaccine were published online in the journal VACCINE. The article concludes that HEPLISAV was well-tolerated and demonstrated superior and mo...
|
|
Dynavax Reports Fourth Quarter and Year End 2011 Financial Results
Mar 6, 2012
|
11.7 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 03/06/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the fourth quarter and year ended December 31, 2011.
Dynavax reported $114 million in cash, cash equivalents and marketable securities, cumulatively referred to as total cash, at December 31, 2011. Th...
|
|
Dynavax to Present at Two Upcoming Investor Healthcare Conferences
Feb 14, 2012
|
7.6 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 02/14/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that Dino Dina, M.D., Chief Executive Officer, will be presenting at the Citigroup 2012 Global Health Care Conference to be held February 27-29, and at the Cowen and Company 32nd Annual Health Care Conference being held March 5-7, 2012....
|
|
Phase 3 Data on HEPLISAV(TM) in Adults Aged 18-55 Published in VACCINE
Feb 13, 2012
|
9.9 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 02/13/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that results of a pivotal Phase 3 trial of HEPLISAV (HBV-10) were published online in the journal VACCINE. Data from this study will be used to support the HEPLISAV Biologics License Application (BLA) submission for an indication in adu...
|
|
Dynavax Reports on Heplisav(TM) Pre-BLA Meeting With FDA
Feb 2, 2012
|
9.5 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 02/02/12 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it met with the Food and Drug Administration (FDA) in a Pre-Biologics License Application (pre-BLA) meeting, and Dynavax and the FDA have agreed that the initial HEPLISAV BLA submission will be for an indication in healthy adults 1...
|
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist for Asthma
Dec 21, 2011
|
9.4 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 12/21/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) and AstraZeneca announced today their decision to advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into IND-enabling preclinical toxicology studies. These toxicology studies are scheduled to be the first module of work perform...
|
|
Dynavax Initiates Proof of Mechanism Trial in Lupus Patients
Dec 20, 2011
|
10.4 KB |
|
| |
BERKELEY, CA -- (MARKETWIRE) -- 12/20/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSm...
|
|
Dynavax Announces Exercise in Full of Overallotment Option and Completion of Public Offering of Common Stock
Nov 8, 2011
|
9.8 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 11/08/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the completion of a public offering of 27,600,000 shares of its common stock, including 3,600,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. All of the shares were offere...
|
|
Dynavax Prices Public Offering of Common Stock
Nov 3, 2011
|
9.9 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 11/03/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of a previously announced underwritten public offering of 24,000,000 shares of its common stock, offered at a price to the public of $2.50 per share. The gross proceeds to Dynavax from this offering are expected to be $60 mi...
|
|
Dynavax Announces Proposed Public Offering of Common Stock
Nov 2, 2011
|
9.6 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 11/02/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to offer and sell shares of its common stock, subject to market and other conditions, in an underwritten public offering. Dynavax also expects to grant the underwriters a 30-day option to purchase additional shares of co...
|
|
Dynavax Confirms HEPLISAV(TM) Submission Strategies With U.S. FDA and EMA
Oct 27, 2011
|
9.5 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today said that the U.S. Food and Drug Administration (FDA) had concurred with the company's plan to submit a Biologics License Application (BLA) for HEPLISAV for persons over 40 years of age, followed by a supplemental BLA for licensure of a specific ...
|
|
Dynavax Reports Third Quarter 2011 Financial Results
Oct 27, 2011
|
15.2 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the third quarter ended September 30, 2011, including $53.2 million in cash, cash equivalents and marketable securities at September 30, 2011. This amount does not include a total of $8.6 million, consisting of $6 mi...
|
|
Dynavax Phase 3 Data in Chronic Kidney Disease Demonstrates Superiority of HEPLISAV(TM) vs Engerix-B(R)
Oct 27, 2011
|
59.0 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/27/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the company has unblinded its Phase 3 primary endpoint immunogenicity data in subjects with chronic kidney disease and that the data achieved statistical significance demonstrating both the superiority and non-inferiority of HEPLISA...
|
|
Data From Two Phase 3 Studies Demonstrate HEPLISAV's Superiority in Immunizing Persons With Diabetes From Hepatitis B
Oct 25, 2011
|
12.5 KB |
|
| |
BERKELEY, CA -- (MARKET WIRE) -- 10/25/11 --
Dynavax Technologies Corporation (NASDAQ: DVAX) today highlighted data from two phase 3 studies of its investigational vaccine HEPLISAV™, one of which was the first clinical trial to prospectively evaluate the effectiveness of vaccinations with recombinant hepatitis B vaccines in patients diag...
|
|
|
